Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
NEW YORK, Oct. 07, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Concordia International Corp. (NASDAQ:CXRX) securities between November 12, 2015 and August 12, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/concordia-international-corp. There is no cost or obligation to you.
According to the complaint, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Concordia was experiencing a substantial increase in market competition against its drug, Donnatal, and other products; (2) as a result, Concordia’s financial results would suffer, and Concordia would be forced to suspend its dividend; and (3) as a result, defendants’ statements about Concordia’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Concordia you have until October 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/concordia-international-corp.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
